EGFR mutations occurred most frequently in glioblastomas (47.3%), esophageal squamous cell carcinoma (17.89%), head and neck squamous cell carcinoma (12.62%), NSCLC (12.16%), esophagogastric adenocarcinomas (10.7%), and diffuse gliomas (10.53%), while pleural mesothelioma, seminoma, well-differentiated thyroid cancer, thymic epithelial tumor, ocular melanoma, and mature B cell neoplasm cohorts were devoid of EGFR mutations (Figure 6A). Here, EGFR is linked to thymic epithelial neoplasm.